Treatment with ixekizumab over 60 weeks provides sustained improvements in health-related quality of life: results from UNCOVER-2, a randomized Phase 3 trial

被引：0

作者：

Warren, R. B. ^{[1
]}

Feldman, S. R. ^{[2
]}

Paul, C. ^{[3
]}

Strand, V. ^{[4
]}

Burge, R. ^{[5
]}

Lin, C. -Y. ^{[5
]}

Goldblum, O. M. ^{[5
]}

Reich, K. ^{[6
]}

机构：

[1] Univ Manchester, Dermatol Ctr, Manchester Acad Hlth Sci Ctr, Salford Royal NHS Fdn Trust, Manchester, Lancs, England

[2] Wake Forest Univ Hlth Sci, Ctr Dermatol Res, Winston Salem, NC USA

[3] Toulouse Univ, Dept Dermatol, Toulouse, France

[4] Stanford Univ, Portola Valley, IN USA

[5] Eli Lilly & Co, Indianapolis, IN 46285 USA

[6] Dermatologikum Hamburg, Hamburg, Germany

来源：

关键词：

DLQI; ixekizumab; quality of life;

D O I：

暂无

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

P141

引用

页码：71 / 71

页数：1